Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHORTened Duration of TAMoxifen for Risk Reduction in Breast Intraepithelial Neoplasms in Post-menopausal Women

NCT07806630 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT07806630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07806630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHORTened Duration of TAMoxifen for Risk Reduction in Breast Intraepithelial Neoplasms in Post-menopausal Women
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 1, 2026
Completion date
July 31, 2029
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk for invasive breast cancer